Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the ability of SB-497115-GR to raise platelet counts
in thrombocytopenic patients with hepatitis C virus (HCV) infection (platelet count <80,000
/μL, suggestive of compensated cirrhosis) to a level desirable to initiate antiviral therapy
and to assess the ability of SB-497115-GR to maintain platelet counts at a level sufficient
to minimise dose reductions of pegylated interferon (Peg-IFN) and ribavirin (RBV) therapy
with the expectation that a lower rate of Peg-IFN dose reduction and omission will translate
to a higher rate of sustained viral response.